Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)

Peer Review reports

Original Submission
18 Jun 2020	Submitted	Original manuscript
30 Oct 2020	Reviewed	Reviewer Report - Kirsty Loudon
22 May 2021	Reviewed	Reviewer Report - Daniel Lovell
23 Aug 2021	Author responded	Author comments - Athimalaipet V Ramanan
Resubmission - Version 2
23 Aug 2021	Submitted	Manuscript version 2
5 Sep 2021	Reviewed	Reviewer Report - Daniel Lovell
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
23 Sep 2021	Editorially accepted
9 Oct 2021	Article published	10.1186/s13063-021-05651-5

Back to article page